While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...